Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The dynamics and longevity of circulating CD4+ memory T cells depend on cell age and not the chronological age of the host.
Bullock ME, Hogan T, Williams C, Morris S, Nowicka M, Sharjeel M, van Dorp C, Yates AJ, Seddon B. Bullock ME, et al. Among authors: seddon b. bioRxiv [Preprint]. 2024 Jun 25:2023.10.16.562650. doi: 10.1101/2023.10.16.562650. bioRxiv. 2024. Update in: PLoS Biol. 2024 Aug 13;22(8):e3002380. doi: 10.1371/journal.pbio.3002380 PMID: 38948729 Free PMC article. Updated. Preprint.
UK guidelines for the management of bone sarcomas.
Gerrand C, Amary F, Anwar HA, Brennan B, Dileo P, Kalkat MS, McCabe MG, McCullough AL, Parry MC, Patel A, Seddon BM, Sherriff JM, Tirabosco R, Strauss SJ. Gerrand C, et al. Among authors: seddon bm. Br J Cancer. 2024 Nov 16. doi: 10.1038/s41416-024-02868-4. Online ahead of print. Br J Cancer. 2024. PMID: 39550489 Review.
Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose-volume constraints development: a study protocol.
Simões R, Gulliford S, Seddon B, Dehbi HM, Robinson M, Forsyth S, Hughes A, Gaunt P, Nguyen TG, Elston S, Mohammed K, Zaidi S, Miles E, Hoskin P, Harrington K, Miah A. Simões R, et al. Among authors: seddon b. BMJ Open. 2024 Aug 9;14(8):e083617. doi: 10.1136/bmjopen-2023-083617. BMJ Open. 2024. PMID: 39122389 Free PMC article.
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.
Mannion J, Gifford V, Bellenie B, Fernando W, Ramos Garcia L, Wilson R, John SW, Udainiya S, Patin EC, Tiu C, Smith A, Goicoechea M, Craxton A, Moraes de Vasconcelos N, Guppy N, Cheung KJ, Cundy NJ, Pierrat O, Brennan A, Roumeliotis TI, Benstead-Hume G, Alexander J, Muirhead G, Layzell S, Lyu W, Roulstone V, Allen M, Baldock H, Legrand A, Gabel F, Serrano-Aparicio N, Starling C, Guo H, Upton J, Gyrd-Hansen M, MacFarlane M, Seddon B, Raynaud F, Roxanis I, Harrington K, Haider S, Choudhary JS, Hoelder S, Tenev T, Meier P. Mannion J, et al. Among authors: seddon b. Immunity. 2024 Jul 9;57(7):1514-1532.e15. doi: 10.1016/j.immuni.2024.04.025. Epub 2024 May 23. Immunity. 2024. PMID: 38788712 Free article.
165 results